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Abstract
Recently, the gene therapy field has begun to experience clinical successes in a number of different diseases
using various approaches and vectors. The workshop Gene Therapy: Charting a Future Course, sponsored by
the National Institutes of Health (NIH) Office of Biotechnology Activities, brought together early and mid-
career researchers to discuss the key scientific challenges and opportunities, ethical and communication issues,
and NIH and foundation resources available to facilitate further clinical advances.
Introduction
Recently, after some years of deferred hopes, anumber of gene therapy trials have demonstrated clini-
cal benefit, including trials for congenital eye diseases
(Hauswirth et al., 2008; Maguire et al., 2008), hereditary
immune system disorders (Aiuti et al., 2009; Hacein-Bey-
Abina et al., 2010; Booth et al., 2011), adoptive transfer of
genetically engineered T cells for cancer (Frantz, 2011;
Porter et al., 2011; Grupp et al., 2013), and gene therapy for
hemophilia B (Nathwani et al., 2011; VandenDriessche and
Chuah, 2012). In 2012, a gene therapy approach for lipo-
protein lipase (LPL) deficiency (Stroes et al., 2008) became
the first gene therapy product licensed in Europe. As the field
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is poised to build on these initial successes, this is an
opportune time to consider the scientific and technological
challenges, ethical and communication issues, and the re-
sources and tools needed to facilitate efficient translation of
gene therapy into clinical practice.
To explore these issues, a workshop titled Gene Therapy:
Charting a Future Course was organized and sponsored by
the National Institutes of Health (NIH) Office of Biotechnol-
ogy Activities (OBA), Office of Science Policy, Office of
the Director. The overall goal was to gather early and mid-
career researchers in conversation with senior scholars in the
field to discuss the key scientific and technical advance-
ments; critical resources that are needed; and the emerging
ethical, biosafety, and communication issues that might be
expected to arise as the field expands. The workshop was
attended by investigators from academia, representatives
from NIH and foundations that support gene therapy re-
search, corporate stakeholders, staff from the Federal Food
and Drug Administration, and members of the NIH Re-
combinant DNA Advisory Committee (RAC). The follow-
ing is a summary of the discussion and represents the views
of the individual authors, not those of NIH. The webcast and
slide presentations from this workshop are available for
review on the OBA website.
Scientific Frontiers for Gene Therapy
Currently, there are over 1200 gene therapy trials registered
with OBA. While the first licensed gene therapy product in
Europe is for a rare disease, and there have been a number of
successful trials for rare inherited immunodeficiencies and eye
disorders, the majority of gene therapy trials target cancer.
This is a maturing field and licensed products in the United
States are also expected in the near future. However, the
majority of protocols registered with OBA from 2010 through
2013 are for early phase trials: 75% are phase I or phase I/II
trials, 21% are phase II, and 4% are phase III. Approximately
one-third of the protocols registered during this period pro-
posed to use retroviruses (including lentiviruses), followed by
DNA plasmids (*19%), adenoviral (Ad) vectors (*15%), and
adeno-associated virus (AAV) vectors (*8%).
To review the current state of the science and define some
of the technical and other challenges, the meeting began
with presentations of novel approaches to the design of
vectors or cell-based systems, and current and upcoming
clinical applications. In the field of oncology a number of
different approaches are being pursued, including immu-
notherapy, oncogene downregulation, tumor suppressors,
vector-directed cell lysis, and suicide genes. In addition,
there have been a number of successful trials for rare dis-
eases, in particular ocular and inherited immunodeficiency
disorders, as well as other inherited neurological and muscle
disorders.
Oncologic applications
Cancer immunotherapy—in particular, T-cell immuno-
therapy—is a major area of research as discussed at a re-
cent NIH workshop, which highlighted the breadth of
research taking place in this arena (http://osp.od.nih.gov/
office-biotechnology-activities/event/2013-09-10-123000-2013-
09-11-161500/scientific-symposium-t-cell-immunotherapy-
optimizing-trial-design). Dr. Nabil Ahmed, Baylor College
of Medicine, summarized the research on genetically en-
gineered T cells for cancer immunotherapy and highlighted
some of the work being done at his institution. The field has
pursued two general approaches: (1) genetically modified
T-cell receptors (TCRs) or (2) chimeric antigen receptors
(CARs), which are artificial receptors, the prototype design of
which includes a variable domain of a tumor-specific anti-
body combined with a T-cell receptor signaling domain
(Eshhar et al., 1993; Pule et al., 2003). While there have been
a number of trials showing promising clinical responses, key
challenges and questions that remain include how to enhance
T-cell survival and expansion (Pule et al., 2008; Savoldo
et al., 2011), whether targeting of multiple antigens will be
required to increase efficacy (Grada et al., 2013; Hegde et al.,
2013), and whether the inclusion of suicide genes (DiStasi
et al., 2011) will ensure efficient and timely elimination of
genetically engineered T-cell products. Future directions will
be aimed at the development of off-the-shelf and broad-
spectrum products that can be rapidly produced (Gerdemann
et al., 2013).
Rather than being a final treatment after standard ther-
apy, the promise of cancer immunotherapy may only be
realized when it is integrated with other therapies such
as surgical debulking, chemotherapy, or other immuno-
modulating agents (Vanneman and Dranoff, 2012). Dr.
Daniel Sterman, University of Pennsylvania, described his
experience studying different gene transfer approaches for
pleural mesothelioma, a disease particularly suited for gene
therapy because the tumor is relatively localized and can be
repeatedly accessed to evaluate tumor and immune responses.
Initial studies were conducted with Ad vectors expressing the
suicide transgene, herpes simplex virus thymidine kinase
(HSV-TK). More recent studies focused on Ad vector de-
livery of interferon transgenes to the pleural space with the
goal of eliciting a global immune response that includes the
generation of antitumor cytotoxic T lymphocytes. Strategies
to improve immunotherapy approaches include treating
earlier stage research participants and defining and modi-
fying their specific immunosuppressive tumor microenvi-
ronment.
Ophthalmologic applications
The eye has proven to be an excellent early target for
gene therapy, offering the ability to directly transduce the
defective cells in a relatively immune-privileged site for
viral vector readministration. Dr. Shannon Boye, University
of Florida, described efforts to extend the success of AAV
gene therapy for RPE65- Leber congenital amaurosis
(LCA2) to other LCA genotypes. LCA1, one of the most
common forms of LCA, is caused by a defect in the guanylate
cyclase 1 (GUCY2D) gene that encodes GC1, a protein ex-
pressed in photoreceptors. Patients with LCA1 have no cone
function; however, their retinas are preserved and present a
target for gene therapy (Jacobson et al., 2013). AAV vectors
derived from various serotypes with different promoters drove
GC1 expression in photoreceptors, restored retinal function
and visually guided behavior, and preserved retinal structure
in multiple animal models of GC1 deficiency (Boye et al.,
2010, 2011, 2013). On the basis of its ability to drive trans-
gene expression exclusively in photoreceptors (foveal and
parafoveal cones and rods) of nonhuman primate, a clinical
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trial is being planned involving subretinal injection of AAV5-
hGRK1-GUCY2D (Boye et al., 2012).
Dr. Boye also discussed two challenges faced in ocular
gene therapy—how to avoid surgical trauma when deliver-
ing vector to patients with inherited retinal degeneration,
and how to overcome the limited carrying capacity of AAV
in order to treat diseases associated with mutations in large
genes. Ocular gene therapy to date has focused on subretinal
delivery, which is a relatively complex surgical procedure.
Dr. Boye discussed how to safely deliver therapeutic genes to
photoreceptors in fragile, degenerate retinas via intravitreal
delivery with vectors that can transverse the inner limiting
membrane to reach photoreceptors. To accomplish this goal,
an understanding of AAV receptor biology and intracellular
trafficking is required. Using rational design and directed
evolution, AAV capsids are being evaluated for transduction
efficiency after intravitreal injection in a mouse model con-
taining sortable photoreceptors. To overcome the limited
carrying capacity of AAV (*5 kb) to allow for the delivery of
larger genes for other retinal disorders, several dual AAV
vector platforms are being investigated. Halves of large genes
can be coadministered by two AAV vectors. Those halves can
then recombine to form a full-length gene once inside the
target cell. Dr. Boye demonstrated the feasibility of using such
dual AAV vector platforms to reconstitute Myosin7A, a large
gene associated with Usher syndrome 1B (Lopes et al., 2013;
Dyka et al., 2014).
Dr. Luk H. Vandenberghe, Harvard Medical School,
discussed the possibility of extending gene therapy to other
ocular diseases, such as LCA caused by other mutations or
other retinal disorders caused by single-gene mutations,
through the development of a platform based on the com-
monalities in the diseases and similar AAV vectors. How-
ever, because the ocular field has a wide spectrum of
monogenetic disorders, it is first important to conduct natural
history studies, which will be essential for the evaluation of
efficacy, determination of biomarkers and end points, and
selection of subject population. He acknowledged that there
are also opportunities to improve vector design, not only by
developing standardized pharmacological assays, and a more
clinically practical method for intravitreal injection, but also
by methods for regulating transgene expression.
Gene transfer for muscle disorders
Another long-standing area of interest for gene therapy
trials is the muscular dystrophies. While there are a number
of protocols focused on gene replacement, Dr. Scott Har-
per’s laboratory at Ohio State University College of Medi-
cine focuses on the use of RNA interference (RNAi) to treat
dominant myopathies by silencing mutant alleles. Dr. Har-
per described his studies of limb girdle muscular dystrophy
1A (LGMD1A), a myopathy in which mutations in the
myotilin (MYOT) gene cause the formation of MYOT pro-
tein aggregates that disrupt the myofibrillar apparatus. In an
LGMD1A mouse model, MYOT-targeted miRNAs knocked
down MYOT expression, reduced aggregate formation, and
improved muscle mass and strength (Liu et al., 2014). While
these results suggested that RNAi should be a useful ap-
proach for dominant negative disorders, Dr. Harper noted a
number of hurdles to translation, including immunology
issues, need for natural history studies, and the challenges of
navigating from preclinical studies through preparation of
investigational new drug (IND) submissions to the FDA and
large-scale vector production.
Advances in ex vivo approaches using hematopoietic
stem cells and induced pluripotent stem cells
The earliest gene therapy trials focused on combined im-
mune deficiencies, using correction of gene defects in hema-
topoietic stem cells (HSCs), and there have been notable
clinical successes reported in multiple trials for adenosine
deaminase deficiency–severe combined immunodeficiency
(ADA-SCID) (Candotti et al., 2012) and for X-linked severe
combined immunodeficiency (Hacein-Bey-Abina et al., 2010),
although for the latter this clinical success came with an un-
acceptable rate of vector-driven hematologic malignancy. Dr.
Satiro De Oliveira, University of California–Los Angeles re-
viewed the uses of CD34 + HSCs transduced ex vivo with
vectors to deliver transgenes for immunodeficiencies (Aiuti
et al., 2009; Hacein-Bey-Abina et al., 2010; Booth et al., 2011),
sickle cell disease (Romero et al., 2013), and b thalassemia, and
the potential to use such cells in cancer immunotherapy (e.g.,
for gene modified T-cell receptors, or CARs) (De Oliveira
et al., 2013; Giannoni et al., 2013). Challenges for the next
generation of clinical trials include development of effi-
cient, minimally genotoxic vectors, standard toxicology
studies, large-scale production of clinical-grade vectors,
and multiphase, milestone-driven research support.
Expanding beyond HSCs as gene therapy targets, Dr.
Yasuhiro Ikeda described his work at the Mayo Clinic with
induced pluripotent stem cell (iPSC) approaches for diabe-
tes. In their lab, biopsy samples from different somatic tis-
sue types were transduced with lentiviral vectors expressing
the four genes necessary for reprograming to iPSCs. These
patient-derived iPSCs were then guided to differentiate
into insulin-producing cells, however, with significant in-
trapatient variation in differentiation (Thatava et al., 2013).
In a mouse model, transplantation of these cells led to ter-
atoma formation, possibly because of insertional mutagen-
esis caused by the lentiviral vector or long-term expression
of the reprogramming factors, which include the c-myc
oncogene. The use of nonintegrating Sendai virus vectors to
decrease the risk of teratomas is currently being tested
(Kudva et al., 2012). While this is a promising approach, the
complex nature of iPSC products raises many challenges to
be overcome before clinical use, including the need for good
manufacturing practice (GMP)–grade reprogramming vec-
tors, reagents used in differentiation, long processing time,
possible autoimmunity issues, and favorable safety records
to balance risk and benefit in a diabetic population with
other therapeutic options.
Improving gene delivery vectors
Many of the ophthalmologic protocols, as well as proto-
cols for hemophilia, muscular dystrophy, and pediatric
neurological diseases, have used AAV vectors. While there
have been a number of successes, immune responses and
gene transfer to off-target tissues are challenges that could
limit this vector’s ability to treat a number of diseases. To
build a stable source of AAV vectors, Dr. Aravind Asokan
at the University of North Carolina is investigating how to
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re-engineer AAV strains to decrease off-target transduction,
increase transduction efficiency in order to decrease needed
vector doses, and escape preexisting immunity (Asokan
et al., 2012). Many AAV serotypes have been isolated that
bind to different receptors, thus displaying different tro-
pisms, which could be useful for specific clinical applica-
tions. In order to fine-tune viral vector tropism, Dr. Asokan
used the knowledge of the various receptor footprints to
manipulate the molecular determinants of tropism by
modifying amino acid side chains to develop, for example,
AAV9 vectors that were detargeted from the liver in order to
increase transduction of heart and skeletal muscles (Asokan
and Samulski, 2013), as well as AAV4 vectors with improved
CNS tropism by modifying the interaction with mucin. A
similar approach is being used to develop vectors that can
evade preexisting immunity by manipulating the footprints of
antibody–antigen interactions. The field of AAV vector de-
velopment has expanded from the few serotypes available in
the 1990s, to the discovery of many more natural serotypes,
to now using a rational engineering approach to design vec-
tors for specific applications. Dr. Asokan pointed out that a
better understanding of cross-species variability in AAV
tropism and transduction efficiency among different preclin-
ical animal models is critical for guiding future trials and
possibly predicting clinical outcomes. Further, it is clear from
ongoing studies that despite their diverse tissue tropisms, the
safety profiles of various AAV strains have been largely
similar, thereby emphasizing the importance of standardized
protocols, safety assessment, and analysis of AAV vectors.
The successes, failures, challenges, and opportunities in
the future for gene therapy as a drug delivery platform were
summarized by Dr. Ronald Crystal, Weill Cornell Medical
College. Compared with other drug delivery systems, gene
therapy has advantages such as sustained and local delivery,
steady-state levels, delivery of intracellular proteins, and the
ability to introduce novel functions into cell types. The field
has succeeded in developing a number of well-defined
vector systems designed for different target cells resulting
in clinical benefits in several indications, including LPL
deficiency, immunodeficiencies, hemophilia B, retinitis pig-
mentosa, and leukemia. Much is still unknown about these
systems however. Among the lessons learned from previous
clinical studies are that innate and adaptive immunity may be
an obstacle; intravascular administration has dose limits; not
all cells can be modified in an organ; and it is more difficult
to downregulate than to upregulate genes. He noted that a
key to the successes seen to date is the ability to target
clinical diseases that have a measurable phenotype.
In addition, he noted that there are a number of unmet needs
in the field, such as the need to improve vector safety and
efficacy. He urged the field to establish standards for vector
production and focus on developing controlled gene expres-
sion. The field should consider developing vectors that can be
targeted into specific sites in the genome or that carry genomic
DNA, rather than focusing on cDNA transgenes.
Finally, as the field matures, it is hoped that it will move
toward developing treatments for more common, acquired
disorders and milder disorders. In addition, it may expand
into complex etiologies, such as underlying biological
mechanisms of psychiatric disorders (e.g., addiction). The
ability to develop safe vectors and have established data to
support clinical safety will be critical. Obviously, as the field
moves from incurable malignancies or fatal rare diseases to
approaches to treat more common and more complex con-
ditions for which there are effective medical or surgical
interventions, the risk–benefit analysis will shift. However,
he argued that the limited funding resources available for
academic research may limit both study size and choice of
indication, so partnership with pharmaceutical, biotechnol-
ogy, or venture capital companies will likely become more
critical if less public resources are available.
Ethical Considerations and Public Perceptions
There are significant bioethical dimensions to all basic
and clinical research, not only to gene therapy. What may be
unique to gene therapy is it comes out of a history of sig-
nificant skepticism and even fear about the biologic, social,
and ethical consequences of genetic manipulation. In the
1970s, questions regarding the safety of genetic manipu-
lation in nonclinical research and fears about unintended
consequences led to public demand for oversight. Rather
than be subject to regulation, the field agreed to self-
regulation and a local oversight system was developed
governed by federal guidelines, the NIH Guidelines for
Research Involving Recombinant or Synthetic Nucleic Acid
Molecules (http://osp.od.nih.gov/office-biotechnology-ac-
tivities/biosafety/nih-guidelines). At the national level, this
system was characterized by transparency and public en-
gagement, with the inclusion of nonscientists, such as law-
yers and bioethicists in decision making. In the more than 40
years since the advent of recombinant DNA technology, the
demonstrated benefits to basic research and the development
of various pharmaceuticals, as well as the increased under-
standing of the associated risks, have led to greater accep-
tance of this technology for many applications.
Clinical research with recombinant DNA started in the
early 1990s and the oversight process, with its transparency,
reassured the American public as this technology moved
into human applications. Gene therapy applications being
targeted today are confined to somatic cell manipulation;
however, for some people not directly involved in its ap-
plication, the perception remains that gene therapy is tar-
geting the fundamental essence of life largely because of the
increasing popular association of personal identity with
nuclear DNA. In addition, because gene therapy had a
challenging and vexed early history, with promise dramat-
ically overstated and few tangible rewards at hand, there
was significant public concern when a clinical gene therapy
trial led directly to the tragic death of a young man, Mr.
Jesse Gelsinger (Zallin, 2000). This tragedy fundamentally
changed the field and the public perceptions of its usefulness
and of the ability of government oversight to adequately
monitor the complexities of a clinical trial, especially those
in which significant financial conflicts of interest were in-
volved and large amounts of money were at stake.
This history surely supports the need for rigorous and
impartial oversight on such issues as informed consent and
refusal processes, transparent data safety and monitoring
systems, conflicts of interests, and ethical issues. This is
especially true as first-in-human trials are brought forth
based on animal data and basic science theories and as the
field moves forward toward new therapies and cures. Re-
searchers must be conscious of not overpromising, remaining
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transparent, and being honest about their successes and
failures. This history also underscores the need for engaging
the public because the new science is advancing rapidly, and
the public may contribute important new questions about the
nature, goal, and meaning of the work.
Finally, gene therapy’s history, with the initial promise
and excitement giving way to a greater understanding of the
complexities of the science after a tragic death, may still
drive the perception of the field. Some individuals, in both
academic and lay circles, may still see gene therapy through
lens colored by its problematic history as an overpromised
technology. Dr. Laurie Zoloth pointed out that in a recent
New York Times article about positive results for hemophilia
gene therapy, the author noted that the disease appears
‘‘treatable by gene therapy, a technique with a 20-year re-
cord of almost unbroken failure’’ (Wade, 2011). While those
in the field would not agree with this assessment, critics in
other disciplines understand this history as a widespread
cautionary tale about science and its promises. It may take a
far stronger and more widespread series of successful trials
to strengthen the acceptance of gene therapy as an estab-
lished medical therapy.
This history may also influence the tolerance for risk from
gene therapy. Whether this perceived lack of tolerance for
risk in new gene therapy trials reflects a general shift re-
garding risk acceptance in any medical research or some-
thing specific to gene therapy is unclear, with some arguing
that gene therapy has been unfairly constrained because of
its history and others providing counter examples (Deakin
et al., 2009; Kimmelman, 2009).
Resources: What Is Available and What Is Needed?
Obtaining funding for basic and clinical research is a
priority for all of the researchers. The participants noted the
need for researchers and institutions to leverage funding
resources, in addition to NIH grants, for clinical trials. Foun-
dations are one such source available to investigators. Foun-
dations represented at the meeting included the Foundation
Fighting Blindness, National Tay-Sachs & Allied Diseases
Association, Inc., Muscular Dystrophy Association, Alli-
ance for Cancer Gene Therapy, and Batten Disease Support
and Research Association (Table 1). Similar to NIH grants,
their process includes scientific peer review scoring; how-
ever, their focus is on developing new innovative thera-
pies for their specific diseases. These foundations have
successfully provided significant translational funding for
clinical work.
The NIH supports a variety of programs that facilitate
translational research. The National Heart, Lung, and
Blood Institute (NHLBI) offers support for translational
gene therapy research through its Gene Therapy Resource
Program (GTRP). The GTRP offers preclinical vectors and
immunology testing; GLP-compliant, IND-enabling phar-
macology and toxicology studies; GMP-grade AAV and
lentivirus vectors; and partial clinical trial funding assis-
tance and regulatory affairs support to qualified investi-
gators. These services are provided at no cost to the
investigator.
Another NHLBI-supported resource is the National Gene
Vector Biorepository (NGVB) and Coordinating Center,
located within the Department of Medical and Molecular
Genetics and the Indiana University School of Medicine.
The NGVB houses a repository that includes a wide range of
plasmids, cell lines, and other reagents submitted by gene
therapy investigators to facilitate broader access to these
novel agents. The NGVB offers archiving services for
specimens from clinical trials and pharmacology/toxicology
studies, as well as for reserve or back-up clinical-grade
vector and master cell banks. The NGVB also maintains a
Table 1. Resources Available for Gene Therapy Research
NIH resources
Gene Therapy Resource Program (GTRP) (www.gtrp.org)
National Heart, Lung, and Blood Institute (NHLBI)–supported program designed to facilitate translation of gene transfer
applications into clinical interventions
Core facilities for preclinical and clinical good manufacturing practice–grade vectors (adeno-associated virus, adeno, and
lentivirus), pharmacology, toxicology, and immunology studies, and a clinical coordinating center
Clinical trial performance and regulatory application support
Genetic Modification Clinical Research Information System (GeMCRIS) (www.gemcris.od.nih.gov/Contents/
GC_HOME.asp)
Information resource and analytical tool that allows public users to access basic reports about gene transfer trials and
develop specific queries (e.g., vector, transgene, medical condition)
Rare Diseases Clinical Research Network (RDCRN) (http://rarediseases.info.nih.gov/ASP/resources/extr_res.asp)
Program coordinated by the Office of Rare Diseases Research, National Center for Advancing Translational Science
(NCATS), to support and facilitate research by creating consortia of research for related rare diseases with the goals of
cost sharing, establishing uniform protocols, and collaborative clinical research
Clinical and Translational Science Award (CTSA) (www.ncats.nih.gov/research/cts/ctsa/about/about.html)
Program within the Division of Clinical Innovation, NCATS, provides funding to individual universities to increase the
efficiency and speed of clinical and translational research across the country.
Foundations Funding Gene Transfer Research
Foundation Fighting Blindness (www.blindness.org/)
National Tay-Sachs & Allied Diseases Association, Inc. (www.ntsad.org/)
Muscular Dystrophy Association (http://mda.org/)
Batten Disease Support and Research Association (www.bdsra.org/)
Alliance for Cancer Gene Therapy (www.acgtfoundation.org/)
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database of pharmacology/toxicology studies previously
conducted to support FDA applications for gene therapy
clinical trials. Upon request from an investigator, the NGVB
will assist with securing letters of cross-reference to allow
the FDA to use this information when reviewing an inves-
tigator’s IND application. The NGVB also offers testing by
linear amplification-mediated PCR and ligation-mediated
PCR technologies for clonal expansion of cells on speci-
mens from clinical trials for which the FDA requires post-
trial monitoring of participants.
NIH recently formed the National Center for Advancing
Translational Science (NCATS). An important program for
academic researchers is the Clinical and Translational Sci-
ence Awards (CTSA). The mission of this program is to
catalyze the generation of innovative methods and tech-
nologies and enhance the development, testing, and im-
plementation of diagnostics and therapeutics. Nationwide,
there are currently 62 sites at academic health centers that
have NIH-funded CTSAs. The overarching goals of each
site and of the national program are to facilitate training and
education of investigators in the full spectrum of transla-
tional science bridging between the bench, the clinic, and
the community and promoting improvements in the quality,
safety, efficiency, and cost-effectiveness of clinical and
translational research (Davis, 2012). Investigators can ac-
cess CTSAs at their institutions. Gene transfer research has
been supported by CTSA at the University of California–
Los Angeles (De Oliveira et al., 2013) and University of
Washington (Till et al., 2013) for CAR T-cell research.
Many gene therapy protocols focus on rare diseases, and
clinical trials for rare diseases raise unique issues, as the
number of subjects available for trials may be limited. In ad-
dition, good data on the natural history of the disease are often
lacking and this may make it more difficult to develop efficacy
endpoints. In response to some of these challenges, in 2003,
the NIH Office of Rare Diseases (ORDR), which is now part of
NCATs, created a Rare Diseases Clinical Research Network
program. The program was developed by ORDR in collabo-
ration with a number of NIH institutes. The network has cre-
ated research consortia that focus on multiple related diseases.
Each consortium must have two multisite clinical studies, one
of which must be a longitudinal study, such as a natural history
study or genotypic–phenotypic correlation study. The consortia
involve multiple investigators and sites and collaborate with
patient advocacy groups and foundations. The goal is to facil-
itate clinical research by making large-scale clinical studies
possible through the development of uniform protocols for data
collection and cost-sharing infrastructure. All consortia are
linked by a single data management and coordinating center
that provides technologies and tools to collect standardized
clinical research data and can also provide support for study
design and data analysis. In addition, the program seeks to
ensure that there is collaboration with patient advocacy
groups, and there is training for new investigators. Currently,
there are 17 consortia with 2290 members, including 97 pa-
tient advocacy groups and foundations. There are 86 clinical
protocols that are accruing research participants. In addition,
174 fellows and new investigators have been trained in
clinical research on rare diseases.
With regard to needed resources, participants noted that
the field would benefit from funding mechanisms that ex-
tend from vector development and preclinical testing
through the initial phases of clinical trials. Once in the clinic
and beyond the initial phase I or small phase II studies, a
potential hurdle will be the ability to scale-up production.
Currently, vector production is decentralized across a num-
ber of institutions. This may be challenging to continue as
products move to commercialization, but as some products
rely on gene modification of autologous cells, this may re-
main a model for certain applications. There was general
agreement that industry support would be needed for opti-
mization of production for commercial application.
Regulatory Frameworks and Commercial Development
One issue raised by investigators was the need for con-
sistency in review standards. The invited mid-career inves-
tigators were largely from academia, with their clinical
studies being funded by NIH or other grants. Many of their
protocols are subject to review by the funding organization,
the NIH Recombinant DNA Advisory Committee, the FDA,
and locally by the Institutional Biosafety Committee and
Institutional Review Board. It was understood that these
bodies have different mandates and expertise. Also noted
was the possibility for inconsistency within a review agency
or body, if over time the staff at an agency or a review
committee changes. A new reviewer or committee member
could raise new issues not raised by the previous reviewer.
Because grant funding is done in 4–5-year cycles, re-
sponding to new recommendations can sometimes make it
difficult to reach the grant endpoint in the time allotted.
Another problem highlighted was the intellectual prop-
erty (IP) issues that can arise with these products. In the
manufacturing of new gene therapy agents, the vectors,
transgenes, promoters, and reagents used may be covered by
different IP claims. IP issues may present a barrier to col-
laboration across institutions for academic researchers. Some
investigators have found that the multiple material transfer
agreements (MTA) that must be signed in order to access
reagents for product development are sometime onerous.
One investigator wondered whether NIH could require that
any product developed with NIH funding uses a universal
MTA that standardizes this process. For pharmaceutical com-
panies, the costs associated with obtaining multiple licenses for
components of a potential gene therapy product may make it
less attractive to pursue such a product compared with one that
has fewer IP constraints. While the meeting participants agree
with the need to protect IP, navigating the licenses for reagents
and component may eventually impede progress. The field
may need to consider innovative strategies to help overcome
some of these hurdles.
Finally, participants voiced uncertainty regarding how
gene therapy products would be reimbursed by insurers and
how that might impact the willingness of pharmaceutical
companies to invest in bringing promising products to
market. Many drugs involve chronic administration result-
ing in a revenue stream over time. A number of gene therapy
applications seek to provide long-term therapeutic benefit
with only a single application, much in the way bone mar-
row transplant does. However, bone marrow transplant is
not a commercial product. If there is uncertainty regarding
the ability to recoup investments from these therapies, it
may be difficult to attract the investment needed to bring
these products forward.
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Biosafety and Long-Term Follow-Up
Gene therapy is unusual among therapeutics in the use of
modified viruses and bacteria that can potentially spread into
the environment and because a number of vectors have the
potential to persist for months or even years. In all clinical
protocols, there is an assessment of immediate safety issues,
but gene therapy has also required assessment of long-term
safety. Currently, the vast majority of gene therapy trials have
enrolled subjects with metastatic or advanced malignancies.
While there have been some notable successes and long-term
survivors, on the whole, the focus on end-stage malignancies
has limited the available long-term follow-up data. In the past
few years, long-term data on children treated with retroviral
vectors in trials for several primary immunodeficiency dis-
orders have been published (Fischer et al., 2013; Mukerjee
and Thrasher, 2013). In addition, several other publications
on long-term follow-up after Ad vector administration for
cardiac disease (Kaminsky et al., 2013) and AAV vectors for
Canavan’s disease (Sondhi et al., 2012) have also been
published. Many additional protocols are beginning to collect
long-term data; however, not all of these data will be pub-
lished. Meeting participants agreed that a central repository
for such data that could be accessed by investigators and the
public would be an important resource that could be used to
support new trials, could allow safety data to be monitored
and assessed, and could lead to the eventual licensing of gene
therapy products. As OBA has access to much of these data, a
central repository could possibly be created by a natural ex-
tension of the current GeMCRIS database.
Another potential issue is the biosafety implications of
certain viral vectors, in particular replication-competent and
oncolytic vectors. While vectors such as AAV are not as-
sociated with human disease, shedding of a modified herpes
or vaccinia virus may raise public health concerns. Even for
vectors that are not likely to lead to human disease (e.g., a
nonreplicating vector derived from an attenuated virus), it
may be important for public acceptance to be able to
Table 2. Opportunities and Challenges Ahead and Resources Needed
Current challenges Future efforts
Need for improved understanding of the
role of specific disease factors in gene
therapy outcomes
Natural history studies to help with
 identification of disease targets with measurable phenotypes
 selection of subject population
 identification of biomarkers
 determination of end points
 evaluation of efficacy
Ability to understand and manage immune
responses to vectors
Vectors designed to evade preexisting immunity
Immune-suppression approaches
Minimizing the risk of toxicity, including
genotoxicity from integrating vectors
that are used for long-term gene
correction
Development of appropriate and validated preclinical assays to
help predict clinical experience
 determine whether data from previous studies could be usefully
shared (e.g., biodistribution of sufficiently equivalent vectors)
Modifications to vectors to decrease the risk of insertional
mutagenesis, e.g.,
 integration into safe harbors
 integration-deficient lentiviral vectors
 genome editing
Controlled transgene expression Development of vectors with
 controlled gene expression
 genomic rather than cDNA transgenes
Refining tissue targeting and improving
transduction efficiency
Vectors targeted to desired cell type
Determination of dose limitations for different routes of administration
Data sharing Enhancement of a central repository accessible to investigators and public
 preclinical data for possible cross-referencing for IND applications
(e.g., expansion of NGVB pharm/tox database)
 long-term follow-up study data (e.g., GeMCRIS)
More frequent publication of this type of data
 e.g., Molecular Therapy Methods, Human Gene Therapy Methods,
Human Gene Therapy Clinical Development
Resources for translational research and
early clinical trials
Multiphase, milestone-driven research support
Industry involvement
Commercialization Large-scale production of clinical-grade vectors
Establishment of reference standards
Standardize MTA across NIH-funded institutions
Pricing models for one-time clinical therapies
Reimbursement models that recognize single-dosing therapies and
will facilitate access
IND, investigational new drug; MTA, material transfer agreements; NGVB, National Gene Vector Biorepository.
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reference expert guidance to confirm that there is a low level
of risk and explain why it is appropriate to deliver such
vectors in an outpatient setting. For replication-competent
viruses, it is critical to generate guidance on whether initial
isolation is warranted and what type of monitoring for shed-
ding or other precautions and counseling should be done.
Every trial with such potential should include a plan for this
risk. Ideally, these plans would be generated by investigators,
informed by guidance established by experts in the field.
Conclusions
The NIH OBA organized this workshop to consider the
most important scientific opportunities on the horizon and to
identify the challenges to realizing these opportunities, in-
cluding knowledge gaps, policy issues, ethical concerns, and
needed resources. The introductory talks touched on a few
of the many promising areas of gene therapy, and new ap-
plications and successes continue to be seen. For example,
in the T-cell immunotherapy area, several reports on gene
therapy trials received much scientific and media attention
when significant clinical responses were seen in adults and
children with advanced leukemia who had exhausted other
approved therapies (Grupp et al., 2013; Davila et al., 2014).
These exciting results highlight the enormous promise of
cancer-targeted T cells. Also in the past year, the OBA has
received a number of protocols proposing first-in-human
approaches for rare diseases that build on the recent suc-
cesses in this area.
Yet even as this field begins to see efficacy, scientific
challenges remain. Participants highlighted the need for
continued refinement of vectors to reduce the risks of im-
mune reactions and allow for better organ or cell targeting,
for example, intravitreal delivery for retinal diseases. If
vector production methods could become more uniform
across protocols, this would facilitate the comparison of
results across clinical trials and could enable investigators to
build more efficiently on these experiences. Further work
should be done to determine how best to integrate gene
therapy approaches into other modalities of care, in partic-
ular for cancer, as the combination of chemotherapy and
gene therapy may provide the optimum benefit.
Together with the need for early career support, the nature
and timeframe for that support are critical issues. For in-
vestigators new to the field, early funding that enables them
to focus on their research rather than needing to balance other
demands, such as clinical duties, may be the key to launching
a gene transfer research program successfully. For clinical
applications, the ideal funding would extend from proof of
concept, through preclinical work, vector production, and the
initial clinical trial. In addition to adequate funding, other
resources considered important included developing uniform
and streamlined MTA for reagents and other materials neces-
sary for gene therapy products developed with the support of
NIH funding. In the regulatory arena, investigators stated that
greater consistency across regulatory reviews, both among in-
stitutions and within agencies, should be a goal.
While some of these issues are not confined to gene
transfer, it was also recognized that these products may raise
specific issues that need to be addressed by the community.
The potential public health risks from replication-competent
vectors derived from viruses associated with human disease
may be low, but nonetheless promoting consistent guide-
lines for the management of research participants who have
received such vectors will be a priority, and OBA will seek
to facilitate this process with investigators. In addition, as
many gene transfer products are able to persist for a number
of years, a means for sharing long-term safety data across
clinical trials would benefit the field, and is another area that
would benefit from NIH stewardship.
The discussions at this workshop helped assess the sci-
entific opportunities and challenges ahead, and resources
needed to assist the field in its progress (Table 2). As the
field approaches what may be its next phase, entering
mainstream medical practice, this group of mid-career in-
vestigators offered their ideas for funding and policy ini-
tiatives that may facilitate this transition.
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